Research Group Experimental Hematology

Mick Milsom
Senior Group Leader

Slider
  • Project funding from the Helmholtz Association

    The Division of Experimental Hematology has been awarded project funding as part of a Helmholtz Association-wide call for funding on future topics relating to health. The consortium is focussed on the topic of Ageing and Metabolic Programming (AMPro) and the funding period will run for three years.

  • Project grant from the MPN Research Foundation

    The Division of Experimental Hematology has been awarded a one year project grant from the MPN Research Foundation to study the effects of interferon-alpha on MPN stem cells.

  • Three year DFG funding for aging-associated epigenetics research

    The Division of Experimental Hematology formed part of a multi-center consortium that successfully applied for a three year funding program from the DFG, to study aging-associated epigenetic as a therapeutic target in acute myeloid leukemia. The Division’s role in the Forschergruppe will be to investigate epigenetic remodelling and clonal selection in a murine model of accelerated hematopoietic stem cell aging, and will be carried out in collaboration with Dr. Daniel Lipka from the Divison of Epigenomics and Cancer Risk Factors.

  • Project Grant for collaborative research with Ben-Gurion University, Israel

    The Division of Experimental Hematology has been awarded a DKFZ-MOST Cooperation in Cancer Research Project Grant in order to fund collaborative research between the Division and the group of Roi Gazit at Ben-Gurion University in Israel.

  • Project grant from the Deutsche Krebshilfe

    In collaboration with the group of Daniel Lipka, in the Division of Epigenomics and Cancer Risk Factors, the Division has been awarded a Project Grant from the Deutsche Krebshilfe to study epigenetic plasticity in pre-leukemic hematopoiesis. March 2017.

  • Natasha Anstee awarded a DKFZ Postdoctoral Fellowship

    Congratulations to Dr. Natasha Anstee, who has been awarded a DKFZ Postdoctoral Fellowship, to fund her work within the group.

  • HI-STEM group leader receives David B. Frohnmayer Award.

    Dr. Michael Milsom was recently awarded the 2016 Fanconi Anemia Research Fund’s David B. Frohnmeyer Early Investigator Award.  The award is given to independent investigators of high accomplishment within 10 years of starting their own group. Dr. Milsom is the second recipient of this award, which was established in 2015 in memory of David Frohnmayer, former Attorney General of the US state of Oregon, President of the University of Oregon, and founder of the Fanconi Anemia Research Foundation.

    Dr. Milsom received this award in light of his pioneering work on the roles of DNA damage and Fanconi anemia signaling pathway function in governing the attrition of hematopoietic stem cells. Dr. Ray Monnat, Chair of the Fanconi Anemia Research Fund Scientific Advisory Board commented that “This is a topic of high, and growing, interest both within the Fanconi anemia community and experimental hematology in general.”

     

     

  • Dr. Mick Milsom elected on to the Board of Directors for the ISEH

    Dr. Mick Milsom has been elected on to the Board of Directors for the International Society for Experimental Hematology (ISEH), for a three year term.

  • HI-STEM scientist’s work recognized with DKFZ award

    Dr. Dagmar Walter and Dr. Amelie Lier were awarded the 2015 Waltraud Lewenz prize for work carried out in the HI-STEM group, Experimental Hematology, led by Dr. Michael Milsom. The prize is awarded annually to young scientists who have published work judged to have furthered the understanding of cancer risk factors, cancer prevention or early detection of cancer. Drs. Walter and Lier were given this award based on the manuscript that they published in the prestigious journal Nature in April 2015, “Exit from dormancy provokes DNA damage-induced attrition in haematopoietic stem cells.”  The manuscript describes how environmental stress factors such as infection, inflammation and injury can lead to hematopoietic stem cell loss and the acquisition of potential cancer-causing mutations within the stem cell compartment.  As well as providing a new mechanism and model to study how cancer develops from the accumulation of DNA mutations within stem cells, this work also sheds new light on how stress-induced stem cell attrition is a likely driving force behind the normal ageing process.

    References

    Walter D., Lier A, Geiselhart A., Thalheimer F.B., Huntscha S., Sobotta M.C., Moehrle B., Brocks D., Bayindir I., Kaschutnig P., Müdder K., Klein C., Jauch A., Schroeder T., Geiger H., Dick T.P., Holland-Letz T., Schmezer P., Lane S.W., Rieger M.A., Essers M.A.G., Williams D.A.W., Trumpp A.and Milsom M.D.(2015). Exit from dormancy provokes DNA damage-induced attrition in haematopoietic stem cells. Nature,520(7548): pp549-552).